- Home
- CNOB vs OCS Comparison
CNOB vs OCS Comparison
Compare CNOB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | OCS |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNOB | OCS |
|---|---|---|
| Price | $27.62 | $20.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $29.50 | ★ $39.80 |
| AVG Volume (30 Days) | ★ 286.1K | 97.6K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $295,956,000.00 | $991,999.00 |
| Revenue This Year | $47.80 | $35.00 |
| Revenue Next Year | $29.35 | $874.12 |
| P/E Ratio | $21.27 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $20.61 | $14.00 |
| 52 Week High | $27.91 | $23.08 |
Technical Indicators
Market Signals| Indicator | CNOB | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 71.48 | 57.99 |
| Support Level | $27.15 | $18.64 |
| Resistance Level | $27.91 | $21.86 |
| Average True Range (ATR) | 0.78 | 0.63 |
| MACD | 0.22 | 0.15 |
| Stochastic Oscillator | 85.62 | 62.42 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.